{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43"}],"title":"Severe"},{"measurements":[{"groupId":"OG000","value":"31"}],"title":"Moderate"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Mild"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Missing"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"description":"Number of participants with Severity of TEAEs during MOR00208 and LEN combination therapy.","groups":[{"description":"MOR00208:\n\nMOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle.\n\nAdditionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.\n\nLEN:\n\nParticipants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings.\n\nOn days when both study drugs were given together, LEN was administered prior to MOR00208.","id":"OG000","title":"Tafasitamab (MOR00208) + Lenalidomide (LEN)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"SAF:\n\nThe SAF includes all participants who received at least one dose of MOR00208 or LEN and had at least one post-baseline safety assessment.","reportingStatus":"POSTED","timeFrame":"Approximately 6.5 years after first participant enrolled","title":"Severity of Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}